Citations

Citations to this article as recorded by  

• The evolving management of endocrine disorders induced by checkpoint inhibitors: insights from the CIITED group
  Priyanka C. Iyer, Nupur Kikani, Sonya Khan, Aysha Chaudhri, Gabriel Pagnotti, Conor Best, Steven Weitzman, Paras Mehta, Victor Lavis, Sonali Thosani, Ayush Gandhi, Rebecca Schneider Aguirre, Jeena Varghese, Theresa Guise, Ramona Dadu
  Expert Review of Endocrinology & Metabolism.2026; 21(1): 29.     CrossRef
• Remission of diabetes with glutamic acid decarboxylase antibody positivity that developed after the administration of olanzapine: a case report
  Kyuho Kim, Soo Hyun Seo, Yun Ji Hong, Woojae Myung, Bomi Kim, Chang Ho Ahn, Sung Hee Choi, Hak Chul Jang, Tae Jung Oh
  Precision and Future Medicine.2026; 10(1): 51.     CrossRef
• Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
  Fumika Kamitani, Yuichi Nishioka, Miyuki Koizumi, Hiroki Nakajima, Yukako Kurematsu, Sadanori Okada, Shinichiro Kubo, Tomoya Myojin, Tatsuya Noda, Tomoaki Imamura, Yutaka Takahashi
  Journal of Diabetes Investigation.2025; 16(2): 334.     CrossRef
• Immune checkpoint inhibitor-related diabetes mellitus associated with high signal intensity in diffusion-weighted magnetic resonance imaging of the pancreas at an early clinical stage
  Masaki Suzuki, Yushi Hirota, Shin Urai, Masaaki Yamamoto, Keitaro Sofue, Wataru Ogawa
  Hormones.2025; 24(2): 569.     CrossRef
• Durvalumab-induced Type 1 Diabetes in a Patient With Pre-existing GADA-positive Diabetes and Preserved Insulin Secretion
  Nobuhiro Nakatake, Megumi Matsuda, Hiroki Kontani
  JCEM Case Reports.2025;[Epub]     CrossRef
• Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model
  Seok Jun Park, Seungwon Yang, Suhyun Lee, Sung Hwan Joo, Taemin Park, Dong Hyun Kim, Hyeonji Kim, Soyun Park, Jung-Tae Kim, Won Gun Kwack, Sung Wook Kang, Yun-Kyoung Song, Jae Myung Cha, Sang Youl Rhee, Eun Kyoung Chung
  Diagnostics.2025; 15(2): 226.     CrossRef
• Risk Factors Associated with the Development of Immune-Checkpoint Inhibitor Diabetes Mellitus: An Integrative Review
  Vivian Crowder, Veronica Brady
  Life.2025; 15(7): 1063.     CrossRef
• Checkpoint Inhibitor-Associated Diabetes Mellitus Following Rapid Pancreatic Metastasis Resolution: Implications for Endocrine Toxicities in Immunotherapy
  Sinead Cadogan, Sadhbh Doherty, Deirdre Kelly, Nigel Glynn
  AACE Endocrinology and Diabetes.2025; 12(4): 339.     CrossRef
• Immune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review
  Kamil Kośmider, Agata Kozakiewicz, Paweł Krawczyk, Robert Kieszko, Katarzyna Szklener, Magdalena Skórzewska, Kamila Wojas-Krawczyk, Ewa Kalinka, Janusz Milanowski
  ImmunoTargets and Therapy.2025; Volume 14: 1455.     CrossRef
• Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab
  Yuma Motomura, Shin Urai, Yushi Hirota, Naoki Takegawa, Hironori Bando, Masaaki Yamamoto, Hidenori Fukuoka, Masahiro Tsuda, Wataru Ogawa
  Diabetology International.2024; 15(1): 130.     CrossRef
• Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors
  Karlijn de Joode, Niels Heersche, Edwin A. Basak, Sander Bins, Astrid A.M. van der Veldt, Ron H.N. van Schaik, Ron H.J. Mathijssen
  Cancer Treatment Reviews.2024; 122: 102662.     CrossRef
• Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes
  Shunya Yabuki, Hiroyuki Hirai, Chihiro Moriya, Yoshiro Kusano, Takeo Hasegawa
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria
  Anna Angelousi, Dimitrios C. Ziogas, Vasiliki Siampanopoulou, Chrysoula Mytareli, Amalia Anastasopoulou, George Lyrarakis, Helen Gogas
  Diseases.2024; 12(2): 40.     CrossRef
• Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
  Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, Dhruv Bansal
  Cancers.2024; 16(6): 1225.     CrossRef
• A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab
  Kota Nishihama, Yuko Okano, Chisa Inoue, Kanako Maki, Kazuhito Eguchi, Soichiro Tanaka, Atsuro Takeshita, Mei Uemura, Taro Yasuma, Toshinari Suzuki, Esteban C. Gabazza, Yutaka Yano
  Diabetology International.2024; 15(3): 583.     CrossRef
• HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis
  Mayo Ono, Mototsugu Nagao, Haruki Takeuchi, Etsuya Fukunaga, Tomoko Nagamine, Kyoko Inagaki, Izumi Fukuda, Masato Iwabu
  European Journal of Endocrinology.2024; 191(1): 9.     CrossRef
• Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus
  Eleni-Rafaela Kani, Eleftheria Karaviti, Dimitra Karaviti, Eleni Gerontiti, Ioanna A. Paschou, Katerina Saltiki, Katerina Stefanaki, Theodora Psaltopoulou, Stavroula A. Paschou
  Endocrine.2024; 87(3): 875.     CrossRef
• A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome
  John Marsiglio, Jordan P. McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami, Douglas Grossmann, Alyssa Erickson-Wayman, Heloisa P. Soares, Katie Kerrigan, Berit Gibson, Jennifer Anne Doherty, John Hyngstrom, Sheetal
  Frontiers in Immunology.2023;[Epub]     CrossRef
• Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
  Almog Shalit, Panagiotis Sarantis, Evangelos Koustas, Eleni-Myrto Trifylli, Dimitris Matthaios, Michalis V. Karamouzis
  Cancers.2023; 15(2): 375.     CrossRef
• Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
  Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero, Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan, David Escors
  Cancers.2023; 15(5): 1629.     CrossRef
• Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors
  Hidefumi Inaba, Shuhei Morita, Daisuke Kosugi, Yuki Asai, Yosuke Kaido, Saya Ito, Tomonao Hirobata, Gen Inoue, Yuki Yamamoto, Masatoshi Jinnin, Hiroaki Kimura, Masao Ota, Yuko Okudaira, Hiroyasu Nakatani, Tomoko Kobayashi, Shintaro Iwama, Hiroshi Arima, T
  Frontiers in Immunology.2023;[Epub]     CrossRef
• Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study
  Natsuko Hara, Hirotsugu Suwanai, Fumiyoshi Yakou, Keitaro Ishii, Hajime Iwasaki, Hironori Abe, Jumpei Shikuma, Hiroyuki Sakai, Takashi Miwa, Ryo Suzuki
  Endocrine.2023; 81(3): 477.     CrossRef
• Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis
  Fiamma Berner, Lukas Flatz
  Immunological Reviews.2023; 318(1): 37.     CrossRef
• Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
  Ichiro Yamauchi, Takuro Hakata, Taku Sugawa, Daisuke Kosugi, Haruka Fujita, Kentaro Okamoto, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Norio Harada, Nobuya Inagaki
  Endocrine Journal.2023; 70(10): 987.     CrossRef
• Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs
  Yihan Zhou, Shan Ding
  Cancers.2023; 15(23): 5622.     CrossRef
• Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer
  Majd Issa, Joy Tang, Yizhen Guo, Chris Coss, Thomas A. Mace, Jason Bischof, Mitch Phelps, Carolyn J Presley, Dwight H Owen
  Expert Review of Anticancer Therapy.2022; 22(8): 861.     CrossRef
• Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
  Adithya Chennamadhavuni, Laith Abushahin, Ning Jin, Carolyn J. Presley, Ashish Manne
  Frontiers in Immunology.2022;[Epub]     CrossRef
• Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice
  Pablo Rodríguez de Vera-Gómez, Ana Piñar-Gutiérrez, Raquel Guerrero-Vázquez, Virginia Bellido, Cristóbal Morales-Portillo, María Pilar Sancho-Márquez, Pablo Espejo-García, Noelia Gros-Herguido, Gema López-Gallardo, María Asunción Martínez-Brocca, Alfonso
  Journal of Diabetes Research.2022; 2022: 1.     CrossRef